Maximum tumor uptake was observed after several hours and retained for several days—a good match to the Ac225 half life. Treatment doses of Ac225-PSMA-617 ranged from 50-200 kBq/kg and dose intervals from 2-4 months. Treatment failure (death or rising PSA) was observed at the lowest dose and severe xerostomia was the limiting factor at higher doses. Based on these data, a standard treatment of 100 kBq/kg every two months was chosen for the second trial.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Presented By: Alfred Morgenstern from European Commission, Joint Research Center, Directorate for Nuclear Safety and Security, Karlsruhe, Germany
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.